Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

This study has been completed.

First Received: December 9, 2005 Last Updated: May 15, 2009 History of Changes

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00264615

Purpose

Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.

Condition	Intervention	Phase
Epilepsy	Drug: lamotrigine extended-release	Phase III

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Single Group Assignment, Pharmacokinetics Study
Official Title:	An Open-Label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-Release to Extended-Release Formulation and Vice Versa

Resource links provided by NLM:

Genetics Home Reference related topics: pyridoxal 5'-phosphate-dependent epilepsy

MedlinePlus related topics: Epilepsy Seizures

Drug Information available for: Lamotrigine

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Steady state AUC(0-24), Cmax and Ct (approximate Cmin) of lamotrigine

Secondary Outcome Measures:

Tmax and fluctuation index of lamotrigine
Adverse events, changes in blood pressure and heart rate
Change in seizure frequency during each of the study phases
Subject preference at End of Baseline and Extended-Release Treatment Phases

Estimated Enrollment:	45
Study Start Date:	October 2005

Eligibility

Ages Eligible for Study:	13 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Confident diagnosis of epilepsy.
Currently on LAMICTAL and up to 2 concomitant AEDs (anti-epileptic drugs).

Exclusion Criteria:

Females of childbearing potential cannot be on hormonal contraceptives or hormone replacement therapy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00264615

Locations

United States, Alabama
GSK Investigational Site
Anniston, Alabama, United States, 36207
United States, Arizona
GSK Investigational Site
Sun City, Arizona, United States, 85351
United States, Kentucky
GSK Investigational Site
Lexington, Kentucky, United States, 40536-0284
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02215
United States, Ohio
GSK Investigational Site
Toledo, Ohio, United States, 43614-5809
United States, Texas
GSK Investigational Site
Dallas, Texas, United States, 75230
United States, Virginia
GSK Investigational Site
Richmond, Virginia, United States, 23219

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials, MD

GlaxoSmithKline

More Information

No publications provided

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	LEP103944
Study First Received:	December 9, 2005
Last Updated:	May 15, 2009
ClinicalTrials.gov Identifier:	NCT00264615 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:

epilepsy
seizure
pharmacokinetics
once daily dosing

Study placed in the following topic categories:

Calcium, Dietary
Epilepsy
Seizures
Lamotrigine
Calcium Channel Blockers

Central Nervous System Diseases
Cardiovascular Agents
Brain Diseases
Anticonvulsants

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action
Nervous System Diseases
Central Nervous System Diseases
Calcium Channel Blockers
Cardiovascular Agents
Brain Diseases
Pharmacologic Actions

Membrane Transport Modulators
Epilepsy
Therapeutic Uses
Lamotrigine
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on July 02, 2009